This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Acute lymphocytic leukaemia, helper endpoint
HLP_C3_ALL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
476 |
4. Check minimum number of eventsNone |
476 |
5. Include endpointsNone |
476 |
6. Filter based on genotype QC (FinnGen only) |
234 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Acute lymphocytic leukaemia, helper endpoint
based on the number of shared cases.
Similar with more cases:
- Acute lymphocytic leukaemia, including Hilmo
- Acute lymphocytic leukaemia
- Liquid cancers
- Liquid cancers, including Hilmo
- Malignant neoplasm
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 234 | 134 | 100 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 9.12 | 7.25 | 11.62 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 259
- Matched controls
- 2587
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L01BB02
ATC
mercaptopurine; oral
384.8
307.7
171
13
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
307.7
249
*
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
305.2
229
*
H02AB02
ATC
dexamethasone; systemic
232.3
304.7
149
15
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
+∞
252.1
199
*
TAB00
NOMESCO Finland
Lumbar puncture
58.8
236.8
155
64
XW000
NOMESCO Finland
Bone marrow biopsy
134.5
229.6
118
16
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
132.4
227.3
117
16
H02AB09
ATC
hydrocortisone; systemic
48.6
190.5
124
48
L04AX03
ATC
methotrexate; systemic
24.7
143.5
125
94
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
68.0
136.6
77
16
TPX10
NOMESCO Finland
Implantation of vascular injection port
65.4
120.3
68
14
A04AA01
ATC
ondansetron; systemic, rectal
34.2
118.1
81
34
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
101.9
91
*
WW500
NOMESCO Finland
Blood transfusion
30.2
84.7
59
25
A41.9
ICD-10 Finland
Sepsis, unspecified
29.1
83.4
59
26
L01BA01
ATC
methotrexate; systemic
27.5
73.9
53
24
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
13.4
71.8
79
82
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
18.3
67.7
59
41
L03AA02
ATC
filgrastim; parenteral
424.8
66.7
64
*
127
Kela drug reimbursment
Transplant complication
23.9
58.5
44
22
9811/3-C42.1
ICD-O-3
B lymphoblastic leukemia/lymphoma, NOS, of bone marrow
+∞
57.4
53
*
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
236.5
56.4
56
*
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
9.9
55.2
75
102
2040A
ICD-9 Finland
Lymphoid leukaemia, Acute
+∞
55.2
51
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
+∞
47.3
44
*
ZX131
NOMESCO Finland
Intrathecal
+∞
46.2
43
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.0
43.4
84
167
R50.9
ICD-10 Finland
Fever, unspecified
5.8
42.5
117
323
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
5.6
39.3
105
280
K03.66
ICD-10 Finland
Tooth plaque
6.0
37.8
86
198
J05AB11
ATC
valaciclovir; oral
6.1
37.6
84
190
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
36.3
34
*
A05AA02
ATC
ursodeoxycholic acid; oral
15.6
36.3
33
24
H02AB06
ATC
prednisolone; systemic
5.0
36.1
158
620
ZXD00
NOMESCO Finland
Emergency procedure
14.4
34.6
33
26
M04AA01
ATC
allopurinol; systemic
9.3
34.3
45
57
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
33.0
31
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
366.4
32.6
32
*
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
+∞
31.9
30
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
31.9
30
*
J02AC01
ATC
fluconazole; systemic
4.4
31.0
130
481
20400
ICD-8 Finland
Lymphatic leukaemia, Acute
+∞
29.7
28
*
ZX114
NOMESCO Finland
Intramuscular
44.6
28.9
35
9
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.1
28.8
58
117
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
28.7
27
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
28.7
27
*
1XX02, ,
NOMESCO Finland
+∞
28.7
27
*
9101
FHL
Bone biopsy
+∞
28.7
27
*
ZX120
NOMESCO Finland
Intravenous
6.9
28.1
48
82
A06AD11
ATC
lactulose; oral
5.9
28.0
58
120
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.7
27.8
84
240
A01AB09
ATC
miconazole; local oral
6.6
26.8
48
86
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
26.5
25
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.4
26.1
87
267
ZXD05
NOMESCO Finland
Urgent procedure
3.9
25.8
117
447
ZXE00
NOMESCO Finland
One hour or less
3.9
25.7
149
670
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.2
25.7
97
326
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
+∞
25.4
24
*
A04AA02
ATC
granisetron; systemic, transdermal
275.2
25.1
25
*
ZX121
NOMESCO Finland
Central venous catheter
74.9
24.3
27
*
J05AB01
ATC
aciclovir; systemic
4.2
23.9
85
272
Z92.6
ICD-10 Finland
Personal history of chemotherapy for neoplastic disease
+∞
23.3
22
*
D64.9
ICD-10 Finland
Anaemia, unspecified
6.5
22.9
41
73
N02AA05
ATC
oxycodone; systemic
6.1
21.6
41
77
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
3.4
21.4
138
645
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
21.1
20
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.5
21.1
114
477
L03AA10
ATC
lenograstim; parenteral
+∞
20.0
19
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
27.2
20.0
27
11
602
Kela drug reimbursment
Children's severe malnutrition
8.5
19.9
27
35
ZX090
NOMESCO Finland
Other technic of radiotherapy
113.7
19.9
21
*
Z3229
NOMESCO Finland
Other healthcare associate professional
4.9
19.6
49
118
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
19.3
123
563
2301
FHL
Lumbar puncture in anesthesia or operating room
+∞
19.0
18
*
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
+∞
19.0
18
*
XF400
NOMESCO Finland
ECG with 12 standard connections
3.8
18.3
70
231
L01BB03
ATC
tioguanine; oral
+∞
17.9
17
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.4
17.7
27
40
121
Kela drug reimbursment
Severe hypofunction of sexual glands
19.1
17.3
26
15
FM2CE, ,
NOMESCO Finland
6.7
17.2
29
48
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.3
16.7
36
76
D70.89
ICD-10 Finland
Neutropenic splenomegaly
43.1
16.6
20
5
WW409
NOMESCO Finland
Other aferesis
+∞
15.8
15
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
15.8
15
*
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
169.6
15.6
16
*
L04AA01
ATC
[U] ciclosporin
30.7
15.4
20
7
R4110
NOMESCO Finland
Physiotherapy
3.0
15.1
94
414
J01MA12
ATC
levofloxacin; systemic
3.9
14.8
49
145
G62.0
ICD-10 Finland
Drug-induced polyneuropathy
84.9
14.7
16
*
Z2446
NOMESCO Finland
Social worker
3.7
14.6
53
167
9109
FHL
Other measure in this category
158.4
14.6
15
*
J02AC03
ATC
voriconazole; systemic
79.4
13.7
15
*
2AX04, ,
NOMESCO Finland
+∞
13.7
13
*
B73
ICPC
Leukaemia
+∞
13.7
13
*
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
6.5
13.6
23
38
B02.9
ICD-10 Finland
Zoster without complication
5.9
13.3
25
46
A02BC01
ATC
omeprazole; systemic
2.9
12.6
77
331
J02AC04
ATC
posaconazole; systemic
+∞
12.6
12
*
WW304
NOMESCO Finland
Transfer of stem cells from registered domestic donator
+∞
12.6
12
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
12.6
12
*
C90.0
ICD-10 Finland
Multiple myeloma
136.2
12.5
13
*
ZXA00
NOMESCO Finland
Right side
3.1
12.4
64
250
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.9
12.3
23
42
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
12.3
86
397
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
12.2
125
694
K00.40
ICD-10 Finland
Postnatal enamel hypoplasia
5.1
11.9
26
55
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
11.5
11
*
L03AA13
ATC
pegfilgrastim; parenteral
125.2
11.5
12
*
Z3226
NOMESCO Finland
Physiotherapist
2.8
11.5
72
312
A01AB04
ATC
amphotericin B; local oral
9.5
11.0
22
25
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
16.4
11.0
17
11
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.1
10.9
24
51
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
22.6
10.8
15
7
JN4BD
NOMESCO Finland
Extensive body CT
9.1
10.8
22
26
L04AD01
ATC
ciclosporin; systemic
9.8
10.7
21
23
2AA01, ,
NOMESCO Finland
+∞
10.5
10
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
10.5
10
*
Z08.2
ICD-10 Finland
Follow-up examination after chemotherapy for malignant neoplasm
+∞
10.5
10
*
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
+∞
10.5
10
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
34.0
10.4
13
*
Z2221
NOMESCO Finland
Medical doctor
2.5
10.1
88
446
0388X
ICD-9 Finland
Septicaemia, Other specified septicaemias
41.8
10.0
12
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.0
9.9
22
47
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
4.0
9.8
30
83
IEP02
NOMESCO Finland
Child-centred family therapy
5.5
9.5
19
37
WB133
NOMESCO Finland
Very demanding adjuvant cytostatic therapy
+∞
9.4
9
*
5639
FHL
Other measure in this category
+∞
9.4
9
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
25.0
9.0
12
5
ZX108
NOMESCO Finland
Inhalation
25.0
9.0
12
5
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.2
9.0
19
39
Z31.6
ICD-10 Finland
General counselling and advice on procreation
10.0
8.9
17
18
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
10.0
8.9
17
18
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.0
8.8
42
155
A03FA01
ATC
metoclopramide; systemic, rectal
3.0
8.7
42
156
WF002
NOMESCO Finland
Radical radiotherapy
51.7
8.7
10
*
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
28.6
8.5
11
*
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
13.4
8.5
14
11
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
92.9
8.5
9
*
5604
FHL
Vascular preparation or cannulation in the operating room
92.9
8.5
9
*
TPW99
NOMESCO Finland
Other minor surgical procedure on peripheral vessel or lymphatic system
11.3
8.4
15
14
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
8.4
70
344
189
Kela drug reimbursment
Imatinib
+∞
8.4
8
*
WA010
NOMESCO Finland
Adjuvant whole body radiotherapy
+∞
8.4
8
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.0
8.2
18
38
J01MA14
ATC
moxifloxacin; systemic
4.0
8.1
24
65
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
8.1
97
555
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
3.2
7.8
32
108
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
15.6
7.8
12
8
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
46.3
7.8
9
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
46.3
7.8
9
*
TDM10
NOMESCO Finland
Puncture of maxillary antrum
4.3
7.7
20
49
K02.0
ICD-10 Finland
Caries limited to enamel
2.1
7.7
107
647
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
7.6
62
300
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
4.5
7.6
19
45
JN4AD
NOMESCO Finland
Body CT examination
6.3
7.5
19
32
I50.1
ICD-10 Finland
Left ventricular failure
9.8
7.4
14
15
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
+∞
7.3
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
TNE20
NOMESCO Finland
Bone marrow aspiration, pelvis
+∞
7.3
7
*
1CX01, ,
NOMESCO Finland
+∞
7.3
7
*
150
Kela drug reimbursment
Dasatinib
+∞
7.3
7
*
L01XE06
ATC
[U] dasatinib
+∞
7.3
7
*
D32.01
ICD-10 Finland
Benign tumor of meninges on interhemispheric surface
+∞
7.3
7
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
3.5
7.3
26
80
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
7.7
7.3
16
22
L04AA06
ATC
mycophenolic acid; systemic
7.7
7.3
16
22
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
3.6
7.3
25
75
EBA15
NOMESCO Finland
Extraction of multiple teeth
4.7
7.3
17
38
QXB05
NOMESCO Finland
Skin wound assessment, unspecified location
30.9
7.2
9
*
SAA03
NOMESCO Finland
Extended examination of mouth
2.0
7.1
148
1026
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
10.4
7.1
13
13
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
7.0
130
865
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.4
7.0
57
276
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
14.3
6.9
11
8
ZXA05
NOMESCO Finland
Left side
2.4
6.8
51
238
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
6.2
6.7
17
29
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.2
6.7
27
90
Z3231
NOMESCO Finland
Registered nurse
2.1
6.7
88
515
SBB20
NOMESCO Finland
Tooth X-ray examination in conjunction with visit to dentist
12.7
6.6
11
9
XF600
NOMESCO Finland
Bloodpressure measurement
2.9
6.6
32
119
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
6.5
6.6
16
26
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.1
6.5
18
46
K00.29
ICD-10 Finland
Other or indefinite deviation in the shape or size of the teeth
71.5
6.5
7
*
M87.3
ICD-10 Finland
Other secondary osteonecrosis
71.5
6.5
7
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
8.5
6.4
13
16
K12.18
ICD-10 Finland
Other forms of stomatitis
18.6
6.3
9
5
J05AX18
ATC
letermovir; oral
+∞
6.3
6
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
+∞
6.3
6
*
0539X
ICD-9 Finland
Herpes zoster without mention of complication
+∞
6.3
6
*
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
+∞
6.3
6
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
+∞
6.3
6
*
Z85.7
ICD-10 Finland
Personal history of other malignant neoplasms of lymphoid, haematopoietic and related tissues
+∞
6.3
6
*
RK224, ,
NOMESCO Finland
+∞
6.3
6
*
130
Kela drug reimbursment
Malignant tumour
+∞
6.3
6
*
E89.5
ICD-10 Finland
Postprocedural testicular hypofunction
+∞
6.3
6
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
6.3
6
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
6.3
6
*
C90.1
ICD-10 Finland
Plasma cell leukaemia
+∞
6.3
6
*
C44.41
ICD-10 Finland
Basocellular carcinoma of the skin of the scalp and neck
+∞
6.3
6
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
4.2
6.3
17
43
EB1JA
NOMESCO Finland
Double panorama tomography of teeth and jaws or similar X-ray examination
27.4
6.3
8
*
TPX15
NOMESCO Finland
Removal of vascular injection port
27.4
6.3
8
*
ZXX02
NOMESCO Finland
Extent of procedure, 2 units
8.0
6.2
13
17
A98
ICPC
Health maint/preventive medicine
0.4
6.1
226
2457
212
Kela drug reimbursment
Gout
12.9
6.1
10
8
WW200
NOMESCO Finland
Immunization
6.3
6.1
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
70
69
13.52
65.50
12.6
1.4
52.46
347.97
e6/l
0.60
56
59
70
70
13.32
64.86
12.6
1.3
8.44
16.50
e6/l
0.32
55
58
55
0
+∞
59.71
22.6
0.0
0.50
—
umol/l
—
55
0
47
27
21.02
58.90
8.4
2.3
132.78
232.09
e6/l
1.39
32
22
45
29
18.55
53.23
6.9
2.6
8.02
10.90
%
0.85
45
29
42
28
17.69
48.72
8.4
2.1
667.00
515.81
e6/l
0.57
27
21
41
28
17.19
46.92
7.2
2.8
—
—
—
0
0
50
52
11.66
44.42
3.8
2.9
12.73
26.90
mu/l
0.89
50
47
55
68
9.99
43.08
4.8
2.0
—
—
—
0
0
45
42
12.74
42.89
4.6
1.7
—
—
—
0
0
76
140
7.26
42.25
3.4
1.9
6.39
7.99
u/l
0.58
52
110
78
153
6.86
40.68
3.3
1.8
9.16
13.43
iu/l
1.09
60
124
35
26
15.39
38.07
8.0
2.3
33.54
21.35
%
4.29
35
26
47
56
10.02
37.66
18.8
9.8
254.43
406.83
iu/ml
—
14
6
51
68
9.08
37.44
4.1
1.8
—
—
—
0
0
40
39
11.93
36.89
3.2
1.9
—
—
—
0
0
63
112
7.10
35.87
21.0
7.0
86.92
94.54
%
1.62
63
112
40
41
11.34
35.63
3.9
1.7
—
—
—
0
0
57
95
7.40
34.41
1.6
1.9
—
—
—
0
0
36
34
12.12
33.81
3.3
1.8
—
—
—
0
0
54
95
6.91
30.83
1.9
1.9
109.91
110.71
au/ml
0.01
26
32
56
113
6.04
27.73
1.5
2.0
110.12
174.30
u/ml
1.93
41
54
91
288
4.32
26.20
18.4
4.5
30.64
30.00
s
0.38
91
283
38
60
7.24
23.77
1.8
1.4
0.27
0.46
nmol/l
0.98
29
49
28
8
38.95
22.55
1.2
1.0
—
—
—
0
0
77
241
4.12
22.12
15.0
4.2
4.74
6.64
umol/l
0.90
69
202
71
213
4.21
21.56
3.6
1.9
—
—
—
0
0
70
212
4.15
20.94
3.7
2.0
—
—
—
0
0
25
30
9.11
19.56
4.8
1.4
—
—
—
0
0
90
338
3.54
19.51
3.1
4.5
578.52
1116.48
ng/l
1.73
75
280
28
39
7.92
19.45
4.4
1.4
—
—
—
0
0
25
31
8.81
19.07
2.4
1.1
—
—
—
0
0
32
54
6.61
18.70
2.9
1.4
—
—
—
0
0
78
276
3.61
18.42
4.9
2.0
—
—
—
0
0
48
121
4.64
18.09
4.4
1.7
—
—
—
0
0
136
689
3.05
17.40
18.1
7.0
35.12
37.32
g/l
4.01
131
662
102
442
3.15
17.17
13.2
2.5
1.85
0.91
mg/l
1.91
87
320
195
1277
3.13
14.54
64.8
8.2
2.89
3.88
e9/l
11.21
183
1078
148
842
2.76
14.40
34.3
11.6
1.22
1.22
mmol/l
0.07
143
793
21
12
18.88
14.08
5.4
2.0
—
—
—
0
0
21
12
18.88
14.08
5.4
2.0
—
—
—
0
0
156
929
2.70
13.58
34.6
10.6
1.23
1.22
mmol/l
0.82
137
849
70
280
3.05
13.10
3.3
2.5
348.06
377.19
nmol/l
0.64
70
269
174
1125
2.66
12.33
24.6
6.8
6.11
6.44
mmol/l
1.52
168
1043
10
0
+∞
10.48
10.2
0.0
—
—
—
0
0
22
45
5.24
10.45
1.7
1.4
—
—
—
0
0
17
14
12.88
10.00
6.8
2.1
33.76
33.21
pg
0.17
17
14
14
7
21.01
9.90
5.1
2.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
48
4.91
9.71
8.5
16.3
0.26
0.30
iu/ml
0.40
14
31
16
13
13.01
9.49
2.1
1.1
—
—
—
0
0
16
13
13.01
9.49
1.3
1.2
—
—
—
0
0
22
50
4.71
9.26
2.2
1.3
—
—
—
0
0
22
50
4.71
9.26
2.2
1.3
—
—
—
0
0
88
465
2.35
9.04
13.0
2.4
—
—
—
0
0
103
596
2.21
8.41
5.2
4.0
0.16
0.25
e6/l
0.54
80
424
8
0
+∞
8.37
1.0
0.0
—
—
—
0
0
23
59
4.18
8.33
1.9
1.5
—
—
—
0
0
114
689
2.17
8.32
13.8
3.0
32.82
33.13
u/l
0.04
114
667
20
49
4.33
7.67
14.7
3.1
3.40
2.28
index
0.46
15
29
11
6
19.04
7.66
10.8
3.3
1.00
1.50
%
—
11
6
28
88
3.44
7.63
47.1
8.5
0.46
0.61
%
1.55
28
88
16
21
8.03
7.50
1.2
1.1
—
—
—
0
0
7
0
+∞
7.32
12.6
0.0
—
—
—
0
0
129
878
1.93
6.30
11.8
2.8
—
—
estimate
—
0
0
6
0
+∞
6.27
4.0
0.0
—
—
—
0
0
48
226
2.38
6.21
42.7
9.1
104.81
104.69
mmol/l
0.06
48
226
62
328
2.17
6.08
44.9
7.6
1.89
1.48
mmol/l
0.75
56
270
18
49
3.87
6.02
72.1
9.8
67.94
67.35
%
0.06
18
49
12
16
7.80
5.69
19.4
2.1
0.83
0.69
index
0.35
12
16
12
16
7.80
5.69
7.7
5.8
—
—
—
0
0
14
28
5.22
5.01
5.6
2.9
—
—
—
0
0
25
95
2.80
4.97
3.0
1.7
—
—
—
0
0
8
7
11.73
4.81
1.6
2.1
—
—
—
0
0
23
86
2.83
4.71
5.5
3.2
1.24
1.23
mmol/l
0.25
23
74
168
1314
1.79
4.68
5.7
4.4
73.88
2017.37
e6/l
—
8
16
15
43
3.64
4.68
2.0
1.7
—
—
—
0
0
11
18
6.32
4.65
1.6
1.0
—
—
—
0
0
27
114
2.52
4.39
49.9
7.6
111.04
129.91
g/l
5.68
27
109
7
6
11.93
4.29
4.6
1.3
—
—
—
0
0
7
6
11.93
4.29
9.1
1.0
—
—
—
0
0
7
6
11.93
4.29
9.1
1.0
—
—
—
0
0
7
6
11.93
4.29
4.6
1.3
—
—
—
0
0
7
6
11.93
4.29
9.1
1.0
—
—
—
0
0
10
18
5.72
4.01
2.9
1.3
—
—
—
0
0
32
154
2.23
3.92
17.9
15.1
0.65
0.56
mmol/l
0.04
23
130
10
19
5.42
3.86
7.7
1.4
—
—
—
0
0
10
19
5.42
3.86
7.7
1.4
—
—
—
0
0
10
19
5.42
3.86
7.7
1.4
—
—
—
0
0
68
432
1.78
3.78
1.6
1.5
17.10
20.32
nmol/l
1.19
62
376
25
110
2.41
3.74
2.2
2.6
102.50
79.30
ml/min/173m2
—
10
43
37
198
2.01
3.46
1.8
1.4
98.68
309.88
u/ml
0.95
32
190
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
22
4.68
3.46
1.4
1.1
—
—
—
0
0
13
37
3.64
3.45
1.9
1.5
—
—
—
0
0
62
395
1.75
3.39
5.5
3.8
0.74
0.75
e6/l
0.02
37
205
7
10
7.15
3.38
9.4
1.2
—
—
—
0
0
7
10
7.15
3.38
9.4
1.2
—
—
—
0
0
7
10
7.15
3.38
9.4
1.2
—
—
—
0
0
7
10
7.15
3.38
9.4
1.2
—
—
—
0
0
82
567
1.65
3.31
2.2
3.2
2.34
2.51
mg/l
0.37
74
501
10
24
4.29
3.22
1.4
1.1
—
—
—
0
0
77
530
1.64
3.14
2.6
2.9
17.00
28.26
ng/l
1.15
51
285
30
154
2.07
3.14
2.0
1.6
343.50
328.92
mu/l
0.08
30
147
5
5
10.15
2.99
1.2
1.0
—
—
—
0
0
8
17
4.81
2.94
2.5
1.8
—
—
—
0
0
16
64
2.60
2.92
1.5
1.1
—
—
—
0
0
27
138
2.07
2.87
2.6
2.8
0.09
0.17
e6/l
0.73
27
130
25
124
2.12
2.86
5.6
2.7
—
—
—
0
0
231
2440
0.50
2.77
81.2
17.7
126.95
136.30
g/l
11.16
231
2413
5
6
8.45
2.76
1.4
2.2
—
—
—
0
0
5
6
8.45
2.76
3.6
1.5
192.20
170.17
u/l
—
5
6
5
6
8.45
2.76
1.4
2.2
—
—
—
0
0
7
14
5.10
2.74
5.3
7.0
—
—
—
0
0
44
272
1.74
2.65
7.5
12.3
1.48
0.83
mmol/l
1.07
36
203
231
2437
0.51
2.63
88.2
18.1
37.91
42.45
%
1.79
231
2412
5
7
7.25
2.56
1.2
1.0
—
—
—
0
0
5
7
7.25
2.56
1.2
1.0
—
—
—
0
0
5
7
7.25
2.56
1.4
2.0
—
—
—
0
0
231
2435
0.51
2.54
80.6
17.4
89.59
88.53
fl
2.48
231
2411
8
21
3.89
2.48
1.6
1.6
—
—
—
0
0
6
12
5.08
2.41
2.0
1.3
—
—
—
0
0
19
91
2.17
2.39
1.5
1.4
—
—
—
0
0
56
383
1.59
2.30
5.9
4.1
2.49
2.95
e6/l
0.18
29
194
187
2062
0.66
2.22
80.7
15.2
336.60
334.46
g/l
2.70
187
2049
6
14
4.35
2.16
2.0
4.1
73.82
140.54
ug/l
—
6
14
74
546
1.50
2.15
3.8
3.6
0.00
0.00
estimate
0.50
27
206
5
10
5.07
2.08
1.2
1.3
—
—
—
0
0
5
10
5.07
2.08
1.2
1.2
—
—
—
0
0
5
10
5.07
2.08
1.2
1.1
—
—
—
0
0
105
836
1.43
2.05
2.2
1.9
—
—
—
0
0
24
134
1.87
2.03
2.7
3.0
5.09
4.79
pmol/l
0.85
24
121
130
1081
1.40
1.96
4.5
3.8
0.00
0.00
estimate
-0.00
30
214
5
11
4.61
1.95
1.2
1.1
—
—
—
0
0
5
11
4.61
1.95
1.2
1.0
—
—
—
0
0
7
22
3.24
1.89
1.0
1.0
—
—
—
0
0
9
34
2.70
1.88
1.8
1.4
—
—
—
0
0
8
28
2.91
1.87
1.4
1.5
—
—
—
0
0
131
1100
1.38
1.82
4.6
3.9
0.00
0.02
estimate
0.65
32
205
130
1092
1.38
1.80
4.7
3.8
0.00
7.08
estimate
0.50
30
213
36
236
1.61
1.76
8.4
12.6
24.97
24.09
mmol/l
2.01
36
231
12
54
2.28
1.76
4.6
1.3
—
—
—
0
0
6
18
3.38
1.75
7.7
1.2
—
—
—
0
0
6
18
3.38
1.75
7.7
1.2
—
—
—
0
0
6
18
3.38
1.75
7.7
1.2
—
—
—
0
0
7
24
2.96
1.73
1.0
1.0
169.29
178.42
mg/l
—
7
24
5
13
3.89
1.72
1.4
1.5
—
—
—
0
0
6
19
3.20
1.67
7.7
1.2
—
—
—
0
0
6
19
3.20
1.67
7.7
1.2
—
—
—
0
0
6
19
3.20
1.67
7.7
1.2
—
—
—
0
0
18
98
1.90
1.66
28.3
16.8
0.66
0.63
%
0.11
18
98
173
1904
0.72
1.64
4.2
3.9
—
—
—
0
0
5
14
3.62
1.62
1.2
1.1
—
—
—
0
0
5
14
3.62
1.62
1.4
2.3
907.00
597.71
u/ml
—
5
14
188
1702
1.38
1.49
28.0
8.9
101.59
96.25
ml/min/173m2
2.40
179
1455
18
103
1.80
1.44
28.3
16.1
94.46
93.99
%
0.15
18
103
18
103
1.80
1.44
28.3
16.1
1.41
1.35
%
0.08
18
103
9
39
2.35
1.44
1.0
1.1
—
—
—
0
0
5
16
3.16
1.44
1.8
1.5
1.56
1.96
mmol/l
—
5
16
50
654
0.71
1.39
2.0
2.5
—
—
—
0
0
6
24
2.53
1.31
1.0
1.0
—
—
—
0
0
8
36
2.26
1.25
1.1
1.1
—
—
—
0
0
5
19
2.66
1.22
1.2
1.1
—
—
—
0
0
5
20
2.53
1.15
1.2
1.2
—
—
—
0
0
5
20
2.53
1.15
1.4
1.5
—
—
—
0
0
44
332
1.39
1.13
3.9
3.7
112.29
652.14
ng/l
0.89
31
202
49
614
0.75
1.02
1.9
2.4
—
—
—
0
0
9
48
1.90
1.01
1.0
1.3
—
—
—
0
0
34
252
1.40
0.98
5.1
1.8
2.45
2.42
mmol/l
0.99
29
216
7
36
1.97
0.97
1.0
1.1
—
—
—
0
0
22
151
1.50
0.93
1.2
1.4
361.62
263.10
miu/ml
—
5
83
229
2188
1.39
0.92
42.6
8.6
36.08
26.05
u/l
6.74
229
2135
211
1993
1.31
0.91
73.5
15.0
13.82
13.20
%
7.90
211
1969
5
101
0.48
0.91
3.0
1.5
74.22
50.39
ug/l
—
5
101
6
29
2.09
0.90
2.5
4.6
7.03
6.51
pmol/l
—
6
29
8
139
0.56
0.86
1.8
1.9
—
—
—
0
0
6
113
0.52
0.85
2.5
1.7
—
—
—
0
0
11
65
1.72
0.83
1.9
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
39
307
1.32
0.79
1.6
1.6
377.61
427.44
pmol/l
0.52
33
280
0
28
0.00
0.76
0.0
1.6
—
20.13
—
0
22
27
202
1.37
0.76
2.6
2.4
21266.71
6353.08
u/l
—
7
81
91
800
1.21
0.73
3.7
3.3
0.00
0.03
estimate
0.96
26
178
12
179
0.65
0.69
1.7
1.4
—
—
—
0
0
20
145
1.41
0.68
13.0
5.3
—
—
—
0
0
8
129
0.61
0.65
2.0
1.7
—
—
—
0
0
62
532
1.22
0.63
3.6
3.1
1.02
1.02
kg/l
0.56
48
333
5
30
1.68
0.61
1.2
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.6
—
—
—
0
0
9
59
1.54
0.55
1.0
1.2
—
12.03
—
0
9
6
96
0.62
0.53
1.2
1.1
0.84
0.86
g/l
—
6
96
78
699
1.16
0.49
2.0
1.9
102.69
96.16
pmol/l
0.48
47
361
18
137
1.34
0.48
1.1
1.5
—
—
—
0
0
6
95
0.62
0.43
1.2
1.1
1.52
1.49
g/l
—
6
95
0
19
0.00
0.39
0.0
1.2
—
0.46
—
0
19
9
67
1.35
0.38
1.0
1.9
46.89
44.47
u/l
—
9
62
14
108
1.31
0.36
1.3
1.5
—
—
—
0
0
41
359
1.17
0.35
1.8
1.5
—
—
—
0
0
67
609
1.13
0.35
3.2
2.9
0.00
0.02
estimate
0.50
23
172
7
52
1.35
0.31
12.9
2.0
—
—
—
0
0
7
53
1.33
0.31
1.6
1.5
—
—
—
0
0
73
787
0.90
0.30
1.5
1.7
0.68
2.12
u/ml
2.10
22
174
41
365
1.14
0.29
1.3
1.3
8.40
28.69
iu/ml
—
8
99
7
56
1.26
0.29
1.4
1.9
1.49
0.60
nmol/l
—
7
49
8
63
1.28
0.28
1.4
1.3
—
—
—
0
0
9
75
1.21
0.25
1.8
1.1
—
—
—
0
0
9
77
1.17
0.24
1.8
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
0.22
—
0
5
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
75.14
—
0
14
0
14
0.00
0.20
0.0
4.5
—
—
—
0
0
15
175
0.85
0.19
1.6
1.2
—
—
—
0
0
6
53
1.13
0.19
4.3
1.9
—
—
—
0
0
37
402
0.91
0.18
2.0
2.3
—
—
—
0
0
15
172
0.86
0.16
4.0
2.4
0.63
0.72
ug/l
—
10
92
21
233
0.89
0.15
4.1
3.3
14.93
23.96
%
—
8
92
11
124
0.88
0.09
1.4
1.6
—
—
—
0
0
5
64
0.78
0.08
1.6
1.8
—
—
—
0
0
20
215
0.92
0.08
1.1
1.1
—
—
—
0
0
41
428
0.95
0.08
4.0
4.3
11.58
46.07
mg/mmol
0.44
33
299
14
128
1.10
0.06
2.7
1.4
0.51
0.27
mg/l
—
6
54
24
228
1.06
0.05
1.2
1.3
161.76
129.90
u/ml
0.22
14
91
11
119
0.92
0.04
2.0
1.4
—
—
—
0
0
13
137
0.95
0.02
1.5
1.7
—
—
—
0
0
33
337
0.97
0.01
1.2
1.3
1.11
8.37
u/ml
2.37
13
127
219
2181
1.02
0.01
53.4
11.7
19.39
21.93
mg/l
0.74
201
1647
11
114
0.96
0.00
1.1
1.4
—
—
—
0
0
34
344
0.99
0.00
1.6
2.1
—
—
—
0
0
16
158
1.01
0.00
1.4
1.3
—
34.88
—
0
6
5
55
0.91
0.00
1.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
10.77
—
0
9
7
79
0.88
-0.00
1.0
1.2
—
19.13
—
0
12
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
13.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
491.14
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
54
0.92
-0.00
2.6
1.3
325.40
347.81
mu/l
—
5
42
0
5
0.00
-0.00
0.0
1.2
—
13.00
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.30
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: HLP_C3_ALL – Acute lymphocytic leukaemia, helper endpoint
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).